Tenax Therapeutics
Levosimendan, a cardiac inotropic agent for heart failure treatment
- Sector
- Biotech
- Founded
- 2008
- Latest Form D
- $99.7M, Aug 2024
- Total capital
- $142M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $142M
- 11 Form D · last Aug 2024
- 26 months since last filing
- Federal contracts
- $185K
- 5 awards · Defense
- Rank in Biotech#299 of 4373
- Granted patents
- 5
- 9 pending · first 2022
- Rank in peer group#269 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 11th filing$99.7M
- Private capital raisedForm D · SEC · 10th filing$8M
- Private capital raisedForm D · SEC · 9th filing$10M
- Private capital raisedForm D · SEC · 8th filing$5.2M
- Private capital raisedForm D · SEC · 7th filing$317K
- Private capital raisedForm D · SEC · 6th filing$6.6M
- Private capital raisedForm D · SEC · 5th filing$4.6M
- Private capital raisedForm D · SEC · 4th filing$53K
- Private capital raisedForm D · SEC · 3rd filing$2.1M
- Offering registeredForm D · SEC · 2nd filing$1.9M
- Private capital raisedForm D · SEC · 1st filing$5.3M
Show 5 earlier federal awards
- Federal contractDefense · Lot # Tbd, Glp-grade (non-gmp)$34K
- Federal contractDefense · Lot #: Tbd, Research Grade (non-gmp/non-$16K
- Federal contractDefense · Glp Grade (non-clinical) Oxycyte$122K
- Federal contractDefense · No Gmp Oxycyte Perfluoro$3K
- Federal contractDefense · Gmp-grade Oxycyte 60% W/v Perflurocarbo$10K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
9months
from Tenax Therapeutics’s first federal award to its first private round.
- First federal award · Aug 2008
- Defense · $10K
- First Form D · Jun 2009
- $5.3M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#269 · top 19%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Stuart RichResearcherExecutive Officer, DirectorLinked by 3 patents
- Anthony A. DiTonnoDirector, Executive OfficerNamed in SEC Form D filings
- Chris A. RallisDirectorNamed in SEC Form D filings
- Christopher T. GiordanoExecutive Officer, DirectorNamed in SEC Form D filings
- Christopher T. GiordanoExecutive Officer, DirectorNamed in SEC Form D filings
- Declan DooganDirectorNamed in SEC Form D filings
Show all 18 people
- Gerald T. ProehlDirectorNamed in SEC Form D filings
- Gerald T. ProehlDirectorNamed in SEC Form D filings
- Gregory R. PepinDirectorNamed in SEC Form D filings
- James R. MitchumDirectorNamed in SEC Form D filings
- June AlmenoffDirectorNamed in SEC Form D filings
- Lawrence R. HoffmanExecutive OfficerNamed in SEC Form D filings
- Lawrence R. HoffmanExecutive OfficerNamed in SEC Form D filings
- Michael DavidsonDirectorNamed in SEC Form D filings
- Michael B. JebsenExecutive OfficerNamed in SEC Form D filings
- Robyn M. HunterDirectorNamed in SEC Form D filings
- Robyn M. HunterDirectorNamed in SEC Form D filings
- Ronald R. BlanckDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 14- GrantedPharmaceutical Compositions For Subcutaneous Administration Of LevosimendanUSPTOUS 12,616,694
- PendingOral Formulations Of Levosimendan For Treating Pulmonary Hypertension With Heart Failure With Preserved Ejection FractionUSPTOApplication 18725602
- PendingUse Of A Combination Of Levosimendan And An SGLT-2 Inhibitor To Treat Heart FailureUSPTOApplication 18714318
Show all 14 patent records
- Pharmaceutical Compositions For Subcutaneous Administration Of LevosimendanMay 5, 2026 · US 12,616,694Granted
- Oral Formulations Of Levosimendan For Treating Pulmonary Hypertension With Heart Failure With Preserved Ejection FractionFeb 27, 2025 · Application 18725602Pending
- Use Of A Combination Of Levosimendan And An SGLT-2 Inhibitor To Treat Heart FailureJan 23, 2025 · Application 18714318Pending
- LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)Aug 15, 2024 · Application 18621976Pending
- LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)Apr 30, 2024 · US 11,969,424Granted
- LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)Jul 18, 2023 · US 11,701,355Granted
- LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)Mar 21, 2023 · US 11,607,412Granted
- Pharmaceutical Compositions for Subcutaneous Administration of LevosimendanJan 4, 2022 · US 11,213,524Granted
- Emulsions Of PerfluorocarbonsAug 25, 2016 · Application 14752416Pending
- Use of Levosimendan to Treat Left Ventricular Systolic Dysfunction in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary BypassDec 31, 2015 · Application 14751476Pending
- Use Of A Combination Of Levosimendan And An SGLT-2 Inhibitor To Treat Heart FailureApplication PCTUS2022080708Pending
- Pharmaceutical Compositions For Subcutaneous Administration Of LevosimendanApplication PCTUS2019047032Pending
- Levosimendan For Treating Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction (ph-hf-pef)Application PCTUS2020065166Pending
- Oral Formulations Of Levosimendan For Treating Pulmonary Hypertension With Heart Failure With Preserved Ejection FractionApplication PCTUS2022082561Pending
Related companies, and why
- Aura BiosciencesSimilar federal contract value in Biotech · $198K in contracts
- GEOVAX, INC.Similar federal contract value in Biotech · $198K in contracts
- Angiocrine BioscienceSimilar federal contract value in Biotech · $189K in contracts
- CANTATA BIO LLCSimilar federal contract value in Biotech · $182K in contracts
- Ambient Biosciences, Inc.Similar federal contract value in Biotech · $180K in contracts
- INTACT GENOMICS INCSimilar federal contract value in Biotech · $168K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .